arrow
M

Mark Yarchoan

Johns Hopkins University
H指数:51
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial

携带KRAS突变肽疫苗及双重检查点封锁的转移性结直肠癌:一项I期临床试验

2026-06-230
OAAI
Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

Publisher Correction: 突变KRAS疫苗联合双重免疫检查点阻断在切除的胰腺癌中的I期临床试验

2026-04-150
OAAI
Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83

全球重分析证实肝母细胞瘤中不存在DNAJB1::PRKACA融合。评述Fleifil等人:DNAJB1-PKAc激酶在年轻儿科肝癌患者中表达并增强致癌通路。Cancers 2025, 17, 83

Cancers
IF4.4
2026-03-120
OAAI
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

携带双检查点阻断的突变KRAS疫苗在切除的胰腺癌中的应用:一项I期临床试验

2026-02-100
OAAI
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial

一种纤维层状肝细胞癌的治疗性多肽疫苗:一项1期临床试验

2025-11-240
OAAI
DNAJ-PKAc induces metabolic rewiring and enhanced glutamine flux in fibrolamellar HCC

DNAJ-PKAc诱导纤维层状肝细胞癌的代谢重编程及谷氨酰胺通量增强

2025-11-060
PRE
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

与接受免疫检查点抑制剂治疗的癌症患者疲劳相关的免疫激活特征

2025-10-010
OAAI
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors

实体瘤患者接受免疫检查点抑制剂治疗后,年龄相关的循环免疫反应差异

2025-04-210
OA
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
2024-10-251
PRE
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
2024-08-290
OAAI